Glaukos completes patient enrolment in Phase II trial of GLK-321

Glaukos has completed patient enrolment in its Phase II clinical trial evaluating GLK-321 for the treatment of Demodex blepharitis, using its iLution platform designed for dropless, transdermal drug delivery. A total of 275 patients have been randomised at clinical sites across the US. The iLution system aims to reduce side effects often linked with traditional eye drop therapies. Credit: SUPERMAO / Shutterstock.com. Glaukos has completed patient enrolment in its Phase II clinical trial evaluating GLK-321 for the treatment of Demodex blepharitis, using its iLution platform designed for dropless, transdermal drug delivery. The double-masked, dose-ranging, multi-centre, placebo-controlled, parallel-group, randomised trial will…

Source: Clinical Trials Arena